<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03249558</url>
  </required_header>
  <id_info>
    <org_study_id>2017P001689</org_study_id>
    <nct_id>NCT03249558</nct_id>
  </id_info>
  <brief_title>Effect of Combined Morphine and Duloxetine on Chronic Pain</brief_title>
  <acronym>Duloxetine</acronym>
  <official_title>Effect of Combined Morphine and Duloxetine on Chronic Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A double-blind, randomized, and placebo-controlled clinical study examining whether
      duloxetine, a serotonin and norepinephrine reuptake inhibitor (SNRI), could enhance opioid
      analgesia and reduce overall opioid use. Positive outcomes will help improve the overall
      effectiveness of clinical opioid therapy and reduce unnecessary opioid dose escalation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2018</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Opioid Dose</measure>
    <time_frame>10 weeks</time_frame>
    <description>The investigators will compare overall opioid dose between the morphine/duloxetine group and the morphine/placebo group and compare rescue dose among all three groups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Analog Scale (VAS)</measure>
    <time_frame>10 weeks</time_frame>
    <description>To examine changes in VAS scores and to determine total versus rescue opioid use after each treatment</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">135</enrollment>
  <condition>Chronic Low Back Pain</condition>
  <condition>Chronic Neck Pain</condition>
  <arm_group>
    <arm_group_label>Morphine, Duloxetine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will take a maximum dose of 60 mg/day of extended release morphine capsules and 60 mg of duloxetine capsules.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Morphine, Placebo Duloxetine</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will take a maximum dose of 60 mg/day of extended release morphine capsules and placebo duloxetine capsules.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Morphine, Duloxetine</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will take placebo morphine capsules and 60 mg of duloxetine capsules.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine</intervention_name>
    <description>Subjects will be randomized into one of the treatment groups and will follow the assigned medication schedule for 10 weeks. Quantitative Sensory Testing (QST) will be performed on the subjects to compare pain threshold, pain tolerance, and wind up.</description>
    <arm_group_label>Morphine, Duloxetine</arm_group_label>
    <arm_group_label>Morphine, Placebo Duloxetine</arm_group_label>
    <other_name>MS Contin, MS IR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duloxetine</intervention_name>
    <description>Subjects will be randomized into one of the treatment groups and will follow the assigned medication schedule for 10 weeks. Quantitative Sensory Testing (QST) will be performed on the subjects to compare pain threshold, pain tolerance, and wind up.</description>
    <arm_group_label>Morphine, Duloxetine</arm_group_label>
    <arm_group_label>Placebo Morphine, Duloxetine</arm_group_label>
    <other_name>Cymbalta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects will be randomized into one of the treatment groups and will follow the assigned medication schedule for 10 weeks. Quantitative Sensory Testing (QST) will be performed on the subjects to compare pain threshold, pain tolerance, and wind up.</description>
    <arm_group_label>Morphine, Placebo Duloxetine</arm_group_label>
    <arm_group_label>Placebo Morphine, Duloxetine</arm_group_label>
    <other_name>Sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject is 18-70 years old.

          2. Subject has chronic neck or back pain for at least 3 months.

          3. Subject has a VAS â‰¥ 5.

          4. Has not taken duloxetine in the last 3 months.

          5. Has not taken an opioid in the last 3 months, but has taken one in the past without
             sufficient pain control OR has never taken opioids but has failed at 3 (or more)
             non-opioid treatments.

        Exclusion Criteria:

          1. Subject has major psychiatric disorders requiring recent hospitalization (within 3
             months) such as major depression, bipolar disorder, schizophrenia, anxiety disorder,
             or psychotic disorder.

          2. Subject is using illicit drugs detected by urine toxicology/drug screen.

          3. Subject is pregnant or lactating/breast feeding.

          4. Subject is allergic to morphine or duloxetine.

          5. Subject is on an antidepressant including serotonin-norepinephrine reuptake inhibitors
             (SNRI), selective serotonin reuptake inhibitor (SSRI), tricyclic antidepressant.

          6. Subject has a history of suicidal attempts or current suicidal ideation.

          7. Subject takes monoamine oxidase inhibitors, antipsychotics, triptan drugs such as
             sumatriptan, lithium, linezolid, tramadol (Ultram), St. John's Wort, central nervous
             system (CNS) stimulants such as amphetamine, methylphenidate, methamphetamine,
             phentermine, diethylpropion, sibutramine, cocaine, or thioridazine.

          8. Subject has uncontrolled narrow-angle glaucoma.

          9. Subject has sensory deficits on arms or Raynaud's Syndrome.

         10. Subject has a pending litigation related to chronic pain condition.

         11. Subject is on methadone or suboxone treatment for addiction.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jianren Mao, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jianren Mao, MD, PhD</last_name>
    <phone>617-724-6102</phone>
    <email>jmao@mgh.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Arissa Opalacz, BA</last_name>
    <phone>617-724-6102</phone>
    <email>aopalacz@partners.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Center for Translational Pain Research</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arissa Opalacz, B.A.</last_name>
      <phone>617-724-6102</phone>
      <email>aopalacz@partners.org</email>
    </contact>
    <contact_backup>
      <last_name>Sarah Roth, B.S.</last_name>
      <phone>617-724-6102</phone>
      <email>sroth3@mgh.harvard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jianren Mao, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.massgeneral.org/painresearch/</url>
    <description>Massachusetts General Hospital Center for Translational Pain Research</description>
  </link>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 11, 2017</study_first_submitted>
  <study_first_submitted_qc>August 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 15, 2017</study_first_posted>
  <last_update_submitted>March 20, 2018</last_update_submitted>
  <last_update_submitted_qc>March 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Jianren Mao, MD, PhD</investigator_full_name>
    <investigator_title>Vice Chair for Research; Chief, Division of Pain Medicine; Director, MGH Center for Translational Pain Research</investigator_title>
  </responsible_party>
  <keyword>Pain</keyword>
  <keyword>Pain Management</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
    <mesh_term>Chronic Pain</mesh_term>
    <mesh_term>Neck Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Duloxetine Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

